Multiple Sclerosis
Conditions
Keywords
stem cell, Multiple Sclerosis, BMMNC
Brief summary
The aim of this study is to prove the BMMNC Therapy in Multiple sclerosis, and to control symptoms and help to maintain a normal quality of life of suffering patients.
Detailed description
Multiple sclerosis (MS) is considered to be an autoimmune disease that is caused by the immune system attacking the central nervous system (CNS) leading to myelin loss and axonal damage, resulting in long-term disability. The pathophysiology of MS is complex with involvement of genetic and environmental factors that define the susceptibility to generate the autoimmune attack. MS is caused by damage to the myelin sheath, the protective covering that surrounds nerve cells. When this nerve covering is damaged, nerve signals slow down or stop.The nerve damage is caused by inflammation. Inflammation occurs when the body's own immune cells attack the nervous system. Currently, treatment of MS relays mainly on immunosuppression combined with monoclonal antibodies and steroid therapies.The most advanced application for MSCs in the neurological clinical arena is in multiple sclerosis.This clinical study time period is for 1 year. This study is carried out to see the role of BMMNC cell Therapy in Multiple sclerosis, and to control symptoms and help to maintain a normal quality of life of suffering patients.
Interventions
BIOLOGICALBMMNC
Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
Sponsors
Chaitanya Hospital, Pune
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Confirmed Diagnosis of MS, Aged 18 - 65 years. Duration of disease: \>5 years Signed, written informed consent Willing and able to comply with study visits according to protocol for the full study period
Exclusion criteria
* Patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results * Patient with any active or chronic infection * No life-threatening organ dysfunction. * Pregnancy or risk of pregnancy. * Patients who are seropositive for HIV1, HIV2, Hepatitis B Surface Antigen, and Hepatitis C * Patients unable to give written informed consent in accordance with research ethics board guidelines * Treatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the 3 months prior to randomization * Treatment with interferon-beta or glatiramer acetate within the 30 days prior to randomization * Treatment with corticosteroids within the 30 days prior to randomization * Current treatment with an investigational therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| analysis of patients symptoms | baseline and 6 months | Improvement in patients symptoms |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| changes in Expanded Kurtzke Disability Status Score scale | baseline and 6 months | The Kurtzke Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis.the evaluation will be done after 6 month |
| changes in clinical variables | baseline and 6 months | — |
| Quality Of life questionnaire | baseline and 6 months | — |
| changes in MRI scan report | baseline and 6 months | — |
| changes in cerebrospinal fluid tests | baseline and 6 months | — |
| Changes in analysis of visual evoked potential test | baseline and 6 months | — |
Countries
India
Contacts
Primary ContactSachin P Jamadar, D.Ortho
Outcome results
None listed